North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine
China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...
North China Pharmaceutical
North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China
North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...
Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers
The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have...